KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $7.3 billion.

  • Jazz Pharmaceuticals' Total Non-Current Liabilities fell 859.25% to $7.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 billion, marking a year-over-year decrease of 859.25%. This contributed to the annual value of $7.8 billion for FY2024, which is 371.15% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $7.3 billion for Q3 2025, which was down 859.25% from $7.1 billion recorded in Q2 2025.
  • Jazz Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $8.9 billion during Q2 2021, with a 5-year trough of $2.9 billion in Q1 2021.
  • In the last 5 years, Jazz Pharmaceuticals' Total Non-Current Liabilities had a median value of $7.6 billion in 2023 and averaged $7.5 billion.
  • In the last 5 years, Jazz Pharmaceuticals' Total Non-Current Liabilities soared by 22076.9% in 2021 and then plummeted by 1205.79% in 2022.
  • Over the past 5 years, Jazz Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $8.2 billion in 2021, then decreased by 6.98% to $7.6 billion in 2022, then decreased by 1.19% to $7.6 billion in 2023, then grew by 3.71% to $7.8 billion in 2024, then fell by 6.94% to $7.3 billion in 2025.
  • Its Total Non-Current Liabilities stands at $7.3 billion for Q3 2025, versus $7.1 billion for Q2 2025 and $7.3 billion for Q1 2025.